{'fraction_non_alphanumeric': 0.02054794520547945, 'fraction_numerical': 0.009784735812133072, 'mean_word_length': 5.6, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa].

We examined the effects of inhaled FK-506, a potent immunosuppressive agent, on increased bronchial responsiveness to acetylcholine and on eosinophil infiltration in a guinea pig models of asthma. The guinea pigs were sensitized by repeated inhalation of ovalbumin (OA). Twenty four hours after antigen challenge, bronchial responsiveness to acetylcholine significantly increased and a marked accumulation of eosinophils in the airways was observed. However, when the guinea pigs were treated with aerosolized FK (10 mg/ml) for 5 min per day for 6 successive days before antigen challenge, the increase in bronchial responsiveness was significantly suppressed and the eosinophil accumulation was strikingly reduced. Since inhaled FK significantly suppressed these responses, there is a possibility that inhaled FK may be a useful therapy for patients with chronic bronchial asthma in the future.